| PolysacDB ID | 2371 |
| Carbohydrate Name | Type 5 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1-
|
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 17-22 |
| Antibody type and class | IgM |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of four different type 5 S. aureus clinical isolates but with none of the five S. aureus clinical isolates possessing type 8 capsular polysaccharides. This Mab was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 6, and 7, but was reactive with type 4 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 19-04-2011
|
| References | 4008045 |